1Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol, 1999,112( Suppl 1):S53-67.
2Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol,2001,19:2334-2356.
3Zhao JX, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic In situ hybridization (CISH) in archival breast carcinoma. Mod Pathol,2002,15: 657-665.
4Jacobs TW, Gown AM, Yaziji H, et al. Specificity of Hercep Test in determining Her-2/neu status of breast cancers using the United States Food and Drug Adminstration-approved scoring system. J Clin Oncol, 1999,17:1983-1987.
5Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol, 2000,53: 890-892.
6Cell Markers And Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/ neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med, 2002,126:803-808.
8Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res, 1994,54:2771-2777.
二级参考文献9
1Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay[J]. CAP Today,1998,12(10) :114-116.
2Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer[ J]. J Pathol,2001,195(4) :422-428.
3Simon R, Nocito A, Hubscher T,et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer[J]. JNatl Cancer Inst,2001,93(15) :1141-1146.
4Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer[J]. J Clin Oncol,2001,19(8) :2334-2356.
5Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression [ J ]. Cancer Res, 1994,54 ( 10 ): 2771-2777.
6Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in DeterminingHer-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. [J]. J Clin Onco1,1999,17(7) :1983-1987.
7Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard [ J ]. Am J Clin Pathol,2001,116(4) :495-503.
8Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. [J]. Am J Clin Pathol,1999,112(Suppl 1 ):S53-67.
9Dunne B, Going JJ. Scoring nuclear pleomorphism in breast cancer[ J ]. Histopathology,2001,39 ( 3 ) :259-265.
